Driving Innovations in Linker Chemistries & Diversifying Conjugation Technologies to Increase ADC Stability & Selectivity

Welcome to the 2nd ADC Linker & Conjugation Summit!

With linker and conjugate deals dominating the ADC industry and more companies shifting their focus towards the chemistries behind linkers and conjugations, innovations in this space are becoming a key point of differentiation to preserve your competitive edge.

The 2nd ADC Linker & Conjugation Summit will provide a technical dive into the chemistries behind stable linkers, exploring click cleavable ADCs and their potential applications in safety and efficacy, optimizing site-specific conjugation production of homogenous DAR, innovative linker and conjugation chemistries for advanced ADC development and more.

This conference is a must-attend for anyone facing challenges with aggregation, cleavable and non-cleavable linkers, site-specific conjugations, working with novel payloads to improve conjugation stability and more. Leave empowered to develop hydrophilic linkers that combat aggregation, understand the ideal level of linker stability, produce ADCs with homogenous DAR, all with the ultimate goal of developing ADCs with high tumour selectivity and efficacy.

Upgrade your resources in this space with unmatched quality in the depth of insights and a community of 100+ topic leaders exclusively working on innovating ADC design through improvement in linker and conjugation technologies.

A snapshot of our 2024 Expert Speaker Faculty

Part of the World ADC Series

Designed to make sure ADC experts are up to date with industry's advancements, the World ADC Event Series unites 1,500+ experts in the field to provide valuable insights and connections to advance ADCs as a first-option treatment. From globally leading conferences to webinars and industry reports, whatever the information you need,  the ADC Linker & Conjugation Summit can offer you the insights you need to maximizing the therapeutic window of ADCs and help to bring safe and effective therapies to market faster.   

Networking 2
Networking 3

2024 Partners: